PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Oral Orforglipron Weight Loss Across Six Trials: Efficacy, GI Tolerability, Gaps

orforglipronglucagon-like peptide-1 receptor agonistoral GLP-1RAobesityoverweighttype 2 diabetesweight losssystematic reviewATTAIN-1ATTAIN-2gastrointestinal adverse events Endocrinology / Diabetes / Obesity

Background Information

Oral orforglipron shows promise for significant weight reduction.

Managing obesity and type 2 diabetes mellitus (T2DM) often requires long-term injectable medications, which can be a barrier for patients. Orforglipron led to body weight reductions of -4.5% to -14.7%, and improved glycemic and metabolic outcomes, with common gastrointestinal side effects. While promising, more long-term trials are needed to determine optimal dosing and safety, limiting immediate clinical application. Orforglipron shows potential as an oral alternative for managing obesity but requires further study.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Paredes Yacaman GJ, Jiménez López AM, Cordova PR, Abad Cuenca SE, Mora López S, Cobos Lladó AI, Bautista Quintero DO, Castillo Bárcena ED, Zamarripa Mottú RA, Zúñiga Flores V, Flores Valdés JR, Montelongo Quevedo M

Citation: Paredes Yacaman GJ, Jiménez López AM, Cordova PR, et al. Efficacy and Safety of Oral Orforglipron for Weight Reduction in Adults With Overweight or Obesity: A Systematic Review. Cureus. 2026;18(10):e117774. doi:10.7759/cureus.117774

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.